1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Dopamine Hydrochloride Injection, USP (Hospira Inc.)

Trade Name: Dopamine Hydrochloride Injection, USP

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as cardiovascular drug

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification: Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Note: No data available

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopamine Hydrochloride</td>
<td>62-31-7</td>
<td>200-527-8</td>
<td>Not Listed</td>
<td>4-8</td>
</tr>
</tbody>
</table>
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EINECS Number</th>
<th>HIN</th>
<th>Proprietary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium metabisulphite</td>
<td>8681-57-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium Citrate</td>
<td>6132-04-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>77-92-9</td>
<td>201-069-1</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures
Eye Contact: Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.

Skin Contact: Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Move to fresh air. If discomfort occurs, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

PZ03084
SAFETY DATA SHEET

Material Name: Dopamine Hydrochloride Injection, USP (Hospira Inc.)
Revision date: 29-Jul-2016

Page 3 of 7

Version: 1.0

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Incompatible Materials: None known
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Dopamine Hydrochloride
Pfizer Occupational Exposure Band (OEB):
OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Odor: No data available.
Molecular Formula: Mixture
Solvent Solubility: No data available
Water Solubility: Soluble
pH: 2.5-5.0
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available
Partition Coefficient: (Method, pH, Endpoint, Value)
Decomposition Temperature (°C): No data available
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: None
Conditions to Avoid: None known
Incompatible Materials: None known
Hazardous Decomposition Products: None known

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include headache, nausea, vomiting, shortness of breath (dyspnea), palpitations, chest pain, increased heart rate (tachycardia), decrease in blood pressure (hypotension).

Acute Toxicity: (Species, Route, End Point, Dose)

Citric acid, anhydrous
Rat Oral LD50 3000 mg/kg

Dopamine Hydrochloride
Rat Oral LD50 2859 mg/kg
Mouse Oral LD50 4361mg/kg
Rat Intravenous LD50 4.8mg/kg
Mouse Intravenous LD50 156mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Citric acid, anhydrous
Eye Irritation Rabbit Severe
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Dopamine Hydrochloride
14 Day(s) Dog No route specified4.5 mg/kg/day NOAEL Gastrointestinal System
14 Day(s) Dog No route specified 13.5 mg/kg/day NOAEL Heart

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Dopamine Hydrochloride
Embryo / Fetal Development Rat No route specified10 mg/kg/day LOAEL Fetotoxicity, Not teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Dopamine Hydrochloride
Bacterial Mutagenicity (Ames) Equivocal
Mouse Lymphoma Assay Positive
In Vivo Micronucleus Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available
SAFETY DATA SHEET

Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Dopamine Hydrochloride
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 200-527-8

Water for Injection
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 231-791-2

Material Name: Dopamine Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 29-Jul-2016
Version: 1.0

Page 6 of 7

PZ03084
15. REGULATORY INFORMATION

sodium metabisulphite
  CERCLA/SARA 313 Emission reporting: Not Listed
  California Proposition 65: Not Listed
  EU EINECS/ELINCS List: Not Listed

Sodium Citrate
  CERCLA/SARA 313 Emission reporting: Not Listed
  California Proposition 65: Not Listed
  Australia (AICS): Present
  EU EINECS/ELINCS List: Not Listed

Citric acid, anhydrous
  CERCLA/SARA 313 Emission reporting: Not Listed
  California Proposition 65: Not Listed
  Inventory - United States TSCA - Sect. 8(b): Present
  Australia (AICS): Present
  EU EINECS/ELINCS List: 201-069-1

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 29-Jul-2016
  Product Stewardship Hazard Communication


Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet